Eltanatama-bcmm sold as Elrexfio, is a pro proved, for adults with relapsed or refractory multiple myeloma who has received at least for prior lines of therapy, including a proteasome inhibitor, an Immodulatory agent and an anti-CD 38 monoclonal antibody.
It is a bispecific B+cell maturation antigen (BCMA) directed CD3, T cell engager.
MagnetisMM-3 study-overall response rate of 57.7% in patients who had received at least four prior lines of therapy.
The median duration of response among responders was not reached after a median five of 11.1 months.
This agent carries a boxed warning for a life-threatening or fatal cytokine release syndrome (CRS) and neurologic toxicity, including immune effect cell associated neurotoxicity.
Because of the risks of CRS and neurologic toxicity, including ICANS, this agent is available only through a restricted program under a REMS.
Adverse reactions include: CRS, fatigue, injection site, reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and pyrexia.
The most common grade 3 to 4 laboratory abnormalities are decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased white blood cells, and decreased platelets.